How PTCL is Diagnosed and Why Protein/Marker Expression is Important
Produced in collaboration with The Leukemia & Lymphoma Society &
T-Cell Leukemia Lymphoma Foundation
Support for this patient education program was provided by Seattle Genetics, Inc.
Peripheral T-cell lymphomas (PTCLs) are uncommon and aggressive types of non-Hodgkin lymphoma (NHL) that develop in mature white blood cells called “T cells” and “natural killer,” or NK, cells. Join us on-demand to hear from clinical specialists, advocates, and families facing PTCLs as they review:
- What information is included in a pathology report, and how it is used to select therapy
- Why a treatment may be switched if there is a relapse
- Effective communication with physicians, including tips for asking questions and seeking a second opinion
Understanding Treatment Options for PTCL
Health care communication and optimizing self-care
Steven Horwitz, MD
Memorial Sloan Kettering Cancer Center
Steven Horwitz, MD, is associate attending of medical oncology in the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York, New York. Dr Horwitz’s research is dedicated to investigating immunotherapeutic approaches to identify better treatments for individuals with T-cell lymphomas and understanding mechanisms of response and resistance to novel drugs in T-cell lymphoma. He participates in several national and international committees dedicated to the advancement of T-cell lymphoma treatment, including as the chair of the National Comprehensive Cancer Network panel on Guidelines for Treatment of T-Cell/Primary Cutaneous B-Cell Lymphomas since 2017. Dr Horwitz earned his medical degree from Case Western Reserve University School of Medicine in Cleveland, Ohio.
Meredith Barnhart, LCSW-R, OSW-C
The Leukemia & Lymphoma Society
Meredith Barnhart is the director of the Information Resource Center at The Leukemia & Lymphoma Society in Rye Brook, New York. She oversees a team of information specialists, who field inquiries from blood cancer patients and their loved ones. Meredith and her team provide comprehensive, personalized, and up-to-date information on the blood cancers, treatment options including clinical trials, and support and financial resources. Her research focuses on the experiences and needs of families with multiple incidences of cancers. She received her master’s degree from Columbia University and is currently pursuing a PhD in social work from the Graduate School of Social Service at Fordham University in New York, New York.
Ilyse Leibowitz, a 51-year-old navigating the twists and turns of a PTCL diagnosis with determination, purpose, and love, was teaching preschoolers and guiding high school athletes through yoga in the spring of 2018 when she received her diagnosis. It came as a surprise to her entire family to receive the news of stage 4 Non-Hodgkin’s Lymphoma. Over the past 2 years, Ilyse has undergone chemotherapy, immunotherapy, and targeted therapy with the support of her husband of 25 years. She has achieved partial remission as the path to a cure is the goal. As a top patient fundraiser and speaker of LIGHT THE NIGHT hosted by the Leukemia & Lymphoma Society (LLS), Ilyse is hopeful new advancements are on the horizon for all who are battling blood cancer.